Although TGF-β/Smad3 has been considered as a major pathway for fibrogenesis, the diverse roles of this pathway in renal inflammation and fibrosis have hampered the development of anti-TGF-β treatment in general 4-7. This evidence concerns the gene SMAD3 and inflammation.